PB0907 - Three-month outcomes in cancer patients with superficial- or deep vein thrombosis in the lower limbs. Results from the RIETE Registry.

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Laurent Bertoletti, MD, PhD

MD, PhD
Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo-Universitaire de Saint-Etienne ; INSERM CIC 1408 CHU de St-Etienne; INSERM UMR 1059, Université Jean Monnet, Saint-Etienne ; FCRIN INNOVTE, France.
Saint-Etienne, Rhone-Alpes, France

Co-Author(s)

PD

Philippe DEBOURDEAU

Dr
Department of Supportive Care Oncology. Institut Sainte Catherine
Avignon, Provence-Alpes-Cote d'Azur, France
CF

Carme Font

MD, PhD
Medical Oncology Service, Hospital Clinic; Barcelona, Spain
Barcelona, Catalonia, Spain
JL

Juan José López-Núñez

Head
Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Barcelona, Catalonia, Spain
CG

Covadonga Gómez-Cuervo

Department of Internal Medicine
Hospital Universitario 12 de Octubre. Madrid. Spain
Madrid, Madrid, Spain
IM

Isabelle MAHE

MD,PhD
Paris Cité University, APHP, Hôpital Louis Mourier, Colombes, Internal Medicine Department, INSERM UMR_S1140, and F-CRIN InnoVTE, France
Colombes, Ile-de-France, France
RO

Remedios Otero

MD, PhD
Pneumology Department, Hospital Universitario Virgen del Rocío-IBIS-US_CIBERES
Seville, Andalucia, Spain
MA

María Dolores ADARRAGA

Dr
Department of Internal Medicine. Hospital Universitario Reina Sofía.
Córdoba, Andalucia, Spain
PL

Patricia LÓPEZ-MIGUEL

Dr
Department of Pneumonology. Hospital General Universitario de Albacete.
Albacete, Andalucia, Spain
MM

Manuel Monreal

MD PhD
Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol. Badalona, Barcelona, Spain Chair for the Study of Thromboembolic Disease, Faculty of Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Spain
Barcelona, Andalucia, Spain

Background: Little is known on superficial vein thrombosis (SVT) management in patients with active cancer

Aims: Describe SVT characteristics and evolution in patients with active cancer.

Methods: Data from the RIETE registry were analyzed to compare the clinical characteristics and 90-day outcomes in patients with active cancer and lower-limb SVT; and compared with two groups: active cancer and lower-limb deep vein thrombosis (DVT); lower-limb SVT without cancer. The primary outcome was subsequent VTE (including symptomatic SVT, DVT or pulmonary embolism (PE)). Secondary outcomes were major bleeding and mortality.

Results: From March 2015 to April 2021, 110 patients with cancer and SVT, 1,695 with cancer and DVT, 1,030 with SVT but no cancer were included in the RIETE registry. Most patients in all subgroups (93%, 99% and 96%, respectively) were anticoagulated, with lower daily doses of low-molecular-weight heparin (114±58, 163±44, and 106±50 IU/kg, respectively) in those with SVT. At 3 months, 101 patients (3.6%) developed subsequent VTE (SVT 13, DVT 41, PE 47), 72 (2.5%) had major bleeding and 282 (9.9%) died. Evolution according to groups are presented in the table. On multivariable analysis, only cancer was found to be an independent predictor for subsequent VTE (HR=2.04; 1.15-3.62).

Conclusion(s): Risk of subsequent VTE (including symptomatic SVT, DVT or PE) are similar in cancer patients with isolated SVT than in those with isolated DVT.